TIZIANALIFESCIENCES.COM: Keyword Density Checker

Total words: 1362 | 2-word phrases: 355 | 3-word phrases: 385 | 4-word phrases: 397

PAGE INFO

Title	Try to keep the title under 60 characters (28 characters) Home - Tiziana Life Sciences
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (102 characters) Developing alternative routes of immunotherapies with innovative drugs for neurodegenerative diseases.

ONE WORD PHRASES 225 Words

#	Keyword	Frequency	Density
1	of	8	3.56%
2	for	8	3.56%
3	tiziana	7	3.11%
4	phase	7	3.11%
5	sclerosis	7	3.11%
6	multiple	6	2.67%
7	and	6	2.67%
8	to	6	2.67%
9	in	6	2.67%
10	life	6	2.67%

TWO WORD PHRASES 355 Words

#	Keyword	Frequency	Density
1	tiziana life	6	1.69%
2	life sciences	6	1.69%
3	secondary progressive	5	1.41%
4	progressive multiple	5	1.41%
5	nonactive secondary	4	1.13%
6	multiple sclerosis	4	1.13%
7	phase 1	3	0.85%
8	clinical trials	3	0.85%
9	phase 2	3	0.85%
10	anti il6	3	0.85%
11	august 2024	2	0.56%
12	in 3q	2	0.56%
13	sclerosis expanded	2	0.56%
14	and neurodegenerative	2	0.56%
15	developing a	2	0.56%
16	we are	2	0.56%
17	find out	2	0.56%
18	out more	2	0.56%
19	learn more	2	0.56%
20	monoclonal antibody	2	0.56%

THREE WORD PHRASES 385 Words

#	Keyword	Frequency	Density
1	tiziana life sciences	6	1.56%
2	secondary progressive multiple	5	1.30%
3	progressive multiple sclerosis	4	1.04%
4	nonactive secondary progressive	4	1.04%
5	neuroinflammatory and neurodegenerative	2	0.52%
6	find out more	2	0.52%
7	monoclonal antibody mab	2	0.52%
8	in 3q 2023	2	0.52%
9	grant from amyotrophic	2	0.52%
10	from amyotrophic lateral	2	0.52%
11	amyotrophic lateral sclerosis	2	0.52%
12	lateral sclerosis association	2	0.52%
13	received in 3q	1	0.26%
14	associated pan kraspositive	1	0.26%
15	with associated pan	1	0.26%
16	subjects with associated	1	0.26%
17	nsclc subjects with	1	0.26%
18	in nsclc subjects	1	0.26%
19	gemcitabine in nsclc	1	0.26%
20	association for development	1	0.26%
21	early onset type	1	0.26%
22	sclerosis association for	1	0.26%
23	ind clearance received	1	0.26%
24	onset type 1	1	0.26%
25	type 1 dm	1	0.26%
26	of milciclib and	1	0.26%
27	combination of milciclib	1	0.26%
28	the combination of	1	0.26%
29	evaluate the combination	1	0.26%
30	clearance received in	1	0.26%

FOUR WORD PHRASES 397 Words

#	Keyword	Frequency	Density
1	secondary progressive multiple sclerosis	4	1.01%
2	nonactive secondary progressive multiple	4	1.01%
3	grant from amyotrophic lateral	2	0.50%
4	from amyotrophic lateral sclerosis	2	0.50%
5	amyotrophic lateral sclerosis association	2	0.50%
6	n10grant from amyotrophic lateral	1	0.25%
7	began in 3q 2023nonactive	1	0.25%
8	in 3q 2023nonactive secondary	1	0.25%
9	3q 2023nonactive secondary progressive	1	0.25%
10	2023nonactive secondary progressive multiple	1	0.25%
11	progressive multiple sclerosis expanded	1	0.25%
12	sclerosis expanded access program	1	0.25%
13	expanded access program n10	1	0.25%
14	combination of milciclib and	1	0.25%
15	evaluate the combination of	1	0.25%
16	the combination of milciclib	1	0.25%
17	phase 2a began in	1	0.25%
18	to evaluate the combination	1	0.25%
19	ind clearance received in	1	0.25%
20	clearance received in 3q	1	0.25%
21	received in 3q 2023	1	0.25%
22	study to evaluate the	1	0.25%
23	a study to evaluate	1	0.25%
24	exploring a study to	1	0.25%
25	are exploring a study	1	0.25%
26	2a began in 3q	1	0.25%
27	in nsclc subjects with	1	0.25%
28	gemcitabine in nsclc subjects	1	0.25%
29	asset is intranasal foralumab	1	0.25%
30	grant awarded by national	1	0.25%
31	matter formulation technologies manufacturing	1	0.25%
32	formulation technologies manufacturing processes	1	0.25%
33	technologies manufacturing processes and	1	0.25%
34	manufacturing processes and disease	1	0.25%
35	million grant awarded by	1	0.25%
36	4 million grant awarded	1	0.25%
37	announces 4 million grant	1	0.25%
38	sciences announces 4 million	1	0.25%
39	lead asset is intranasal	1	0.25%
40	life sciences announces 4	1	0.25%